Quicksilver II pilot study for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This pilot study tests a new approach for people with early-stage rectal cancer that was completely removed. It aims to improve outcomes by giving additional treatment after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have rectal cancer that is stage II or III, and it was removed completely with clear margins (no cancer left at the edges).
- You do not need a permanent colostomy (a bag for stool).
- Your tumor is not T4 (it hasn't grown into nearby organs).
- You do not have enlarged lymph nodes in the side wall of your pelvis (larger than 7 mm).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a short course of radiation therapy combined with chemotherapy for people with stage II or III rectal cancer. It’s designed to see whether this approach is safe and effective before or around cancer surgery.
This Phase 2 trial compares a pre-surgery (neoadjuvant) treatment plan versus the standard plan for people with stage II–III rectal cancer. The goal is to see which approach works better and is safe before surgery.
This trial studies whether a period of active surveillance (watching closely) and chemotherapy before surgery can improve outcomes for people with stage II–III rectal cancer. You would also receive standard chemo-radiation if you qualify, then proceed to surgery.
This study compares two standard treatment approaches for early-stage rectal cancer that has not spread. One group gets chemo and radiation before surgery, while the other gets chemo, radiation, and more chemo before surgery. The goal is to see which plan is more effective and has fewer side effects.
This study looks at whether it’s practical and safe to treat certain rectal cancers without surgery. You may be offered non-surgical (“neoadjuvant”) treatment and close follow-up to see how well it works in a rural setting.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
Hear when a new Stage II Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.